Discovery Biology
Accelerate drug target validation and development with EnquBio’s Discovery Services. Our expert team integrates genome editing, custom cell line generation, iPSC models, and functional assays to connect targets to phenotypes across diverse therapeutic areas. Leveraging advanced platforms and cost-effective workflows, we streamline early-stage research so you can focus on selecting and advancing your most promising candidates.
Genome Editing
EnquBio delivers advanced gene editing solutions using CRISPR/Cas9 technology to accelerate in vitro disease modeling and therapeutic discovery. Our established platform supports a wide spectrum of genetic modifications, including conventional and conditional knockouts, multi-gene knockdowns, and knock-ins across diverse cell systems such as tumor lines, primary cells, and iPSCs. With extensive experience driving complex editing programs, we are equipped to address even the most demanding research challenges.
Cell Line Generation
EnquBio provides custom cell line development services tailored to your specific research objectives. Our capabilities include cell immortalization, gene overexpression, knockdown, knockout, site-specific mutation, and fragment or tag knock-in. With deep expertise in complex cell engineering, our team offers strategic scientific guidance and delivers rapid, high-quality, and fully validated cell lines optimized for screening, functional studies, and assay development.
Induced Pluripotent Stem Cell (iPSC) Platform
EnquBio’s integrated induced pluripotent stem cell (iPSC) platform provides end-to-end solutions for disease modeling and target validation. We create iPSC lines from both healthy and patient-derived samples, offering full characterization, precise gene editing, and differentiation into disease-relevant cell types such as cardiomyocytes and neurons. Our services also encompass biobanking and high-content screening with iPSCs or iPSC-derived cells. By delivering a human-relevant, genetically accurate system, our platform bridges translational gaps and drives robust target discovery.
Mechanism of Action (MOA) & Exploratory Biology
Robust technology platforms provide comprehensive support to help our partners uncover mechanisms of action, from downstream pathway analysis and phenotypic characterization to transcriptomic profiling. We deliver actionable insights that enable early validation and effective target prioritization. With a proven record in exploratory research, including publication, and proof-of-concept studies, we design tailored experiments leveraging multi-omics integration, CRISPR-based functional assays, and high-content imaging. Our approach generates deep biological insights and enhances the discovery of innovative therapies.